<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408120</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00078695</org_study_id>
    <nct_id>NCT02408120</nct_id>
  </id_info>
  <brief_title>Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes</brief_title>
  <official_title>Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes Treated With Basal Bolus Insulin Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether using extra doses of aspart insulin to correct&#xD;
      blood sugars before meals improves the care of patients with type 2 diabetes in the hospital&#xD;
      who are already receiving the standard of care treatment with glargine and aspart insulin&#xD;
      injections to control blood sugar levels. Studies done in the past indicate that blood sugar&#xD;
      levels are controlled on the standard treatment of insulin and that most patients do not need&#xD;
      the small extra dose of insulin at bedtime. The investigators want to test if there is any&#xD;
      benefit to giving patients extra doses of insulin during the day to correct the high blood&#xD;
      sugars.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The management of patients with Type 2 diabetes involves treatment with two different types&#xD;
      of insulin injections to control blood sugar levels. The doses of the two types of insulins,&#xD;
      glargine insulin and aspart insulin are adjusted daily through the hospital stay based on&#xD;
      blood sugar levels. Many times, in addition to glargine and aspart insulin at meals,&#xD;
      additional small doses of aspart insulin are given to correct high blood sugar levels. It has&#xD;
      not been determined if using these extra doses of aspart insulin to correct blood sugars&#xD;
      before meals improves care of the patients. Studies done in the past indicate that blood&#xD;
      sugar levels are well controlled on the standard treatment of the two insulins and that most&#xD;
      patients do not need the small extra dose of insulin at bedtime. This study will test if&#xD;
      insulin supplementation improves glycemic control and prevents hypoglycemia in insulin&#xD;
      treated patients with type 2 diabetes mellitus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 11, 2019</completion_date>
  <primary_completion_date type="Actual">December 11, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Daily BG Levels</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>Blood glucose (BG) will be measured, and mean daily BG levels will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Glucose Levels Before Lunch</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The blood glucose levels will be assessed prior to lunch using a glucose meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Glucose Levels at Bedtime</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The blood glucose levels will be assessed at bedtime using a glucose meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Glucose Levels Before Dinner</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The blood glucose levels will be assessed before dinner using a glucose meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hypoglycemia</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The number of occurrences of hypoglycemia (blood glucose levels &lt; 70 mg/dL) will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hyperglycemia</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The number of occurrences of hyperglycemia (blood glucose levels &gt; 260 mg/dL) will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Blood Glucose Readings Within 100-140 mg/dL Range</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The number of blood glucose readings that are in the target range of 100-140 mg/dL will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Number of Days of Hospital Stay</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The average number of days in the hospital for subjects will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The total number of subject deaths during hospital stay will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects That Experienced Hospital Complications</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>The total number of subjects in which hospital complications occurred prior to discharge will be recorded. These complications will mainly be cases of nosocomial infections, pneumonia, bacteremia, respiratory failure, and acute kidney injury [rise of serum creatinine &gt;0.5 mg/dL (or 50%) of baseline value]. Nosocomial infections will be diagnosed based on standardized Centers for Disease Control (CDC) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Dose of Insulin</measure>
    <time_frame>5 days (average time of discharge from the hospital)</time_frame>
    <description>Daily dose of insulin will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">226</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin Aspart for BG &gt; 140 mg/dL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Aspart for BG &gt; 260 mg/dL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Half of total daily dose (TDD) will be given as insulin glargine and will be given once daily, at the same time of the day.&#xD;
Daily insulin dose will be adjusted as follow:&#xD;
If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change&#xD;
If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day&#xD;
If the fasting and pre-dinner BG is &gt;180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day&#xD;
If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day&#xD;
If a patient develops hypoglycemia (BG &lt;70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%.</description>
    <arm_group_label>Insulin Aspart for BG &gt; 140 mg/dL</arm_group_label>
    <arm_group_label>Insulin Aspart for BG &gt; 260 mg/dL</arm_group_label>
    <other_name>Lantus (glargine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin aspart</intervention_name>
    <description>Half of total daily dose will be given as insulin aspart and in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, the dose of aspart will be held.&#xD;
Daily insulin dose will be adjusted as follow:&#xD;
If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change&#xD;
If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day&#xD;
If the fasting and pre-dinner BG is &gt;180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day&#xD;
If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day&#xD;
If a patient develops hypoglycemia (BG &lt;70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%.</description>
    <arm_group_label>Insulin Aspart for BG &gt; 140 mg/dL</arm_group_label>
    <arm_group_label>Insulin Aspart for BG &gt; 260 mg/dL</arm_group_label>
    <other_name>Novolog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Supplemental insulin aspart</intervention_name>
    <description>Insulin aspart will be administered following the supplemental insulin scale protocol.&#xD;
For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:&#xD;
BG &gt;141-180 mg/dL; 2-4 units of insulin aspart&#xD;
BG between 181-220 mg/dL; 3-6 units of insulin aspart&#xD;
BG between 221-260 mg/dL; 4-8 units of insulin aspart&#xD;
BG between 261-300 mg/dL; 5-10 units of insulin aspart&#xD;
BG between 301-350 mg/dL; 6-12 units of insulin aspart&#xD;
BG between 351-400 mg/dL; 7-14 units of insulin aspart&#xD;
BG &gt; 400 mg/dL; 8-16 units of insulin aspart&#xD;
For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:&#xD;
BG between 261-300 mg/dL; 5-10 units of insulin aspart&#xD;
BG between 301-350 mg/dL; 6-12 units of insulin aspart&#xD;
BG between 351-400 mg/dL; 7-14 units of insulin aspart&#xD;
BG &gt; 400 mg/dL; 8-16 units of insulin aspart</description>
    <arm_group_label>Insulin Aspart for BG &gt; 140 mg/dL</arm_group_label>
    <arm_group_label>Insulin Aspart for BG &gt; 260 mg/dL</arm_group_label>
    <other_name>Novolog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects admitted to the hospital with acute or chronic medical illnesses or for&#xD;
             elective and emergency surgical illness or trauma&#xD;
&#xD;
          2. Known history of Type 2 diabetes mellitus for &gt;3 months&#xD;
&#xD;
          3. Treated with either diet alone, any combination of oral antidiabetic agents,&#xD;
             non-insulin injectables or insulin therapy&#xD;
&#xD;
          4. Blood glucose levels between &gt;140 mg and &lt;400 mg/dL without laboratory evidence of&#xD;
             diabetic ketoacidosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hyperglycemia without a history of diabetes&#xD;
&#xD;
          2. Subjects with acute critical illness admitted to the ICU or expected to require ICU&#xD;
             admission&#xD;
&#xD;
          3. Subjects receiving continuous insulin infusion&#xD;
&#xD;
          4. Clinically relevant hepatic disease&#xD;
&#xD;
          5. Corticosteroid therapy&#xD;
&#xD;
          6. Serum creatinine â‰¥ 3.5 mg/dL and/or glomerular filtration rate (GFR) &lt;30&#xD;
&#xD;
          7. Subjects unable to sign consent&#xD;
&#xD;
          8. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priyathama Vellanki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <results_first_submitted>December 10, 2020</results_first_submitted>
  <results_first_submitted_qc>December 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 6, 2021</results_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Priyathama Vellanki</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Hyperglycemia</keyword>
  <keyword>Hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02408120/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
          <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
        </group>
        <group group_id="P2">
          <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
          <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Refusal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received Steroids</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discharged same day</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive insulin</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
          <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
        </group>
        <group group_id="B2">
          <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
          <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="215"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Daily BG Levels</title>
        <description>Blood glucose (BG) will be measured, and mean daily BG levels will be calculated.</description>
        <time_frame>5 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily BG Levels</title>
          <description>Blood glucose (BG) will be measured, and mean daily BG levels will be calculated.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172" spread="38.2"/>
                    <measurement group_id="O2" value="173" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Glucose Levels Before Lunch</title>
        <description>The blood glucose levels will be assessed prior to lunch using a glucose meter.</description>
        <time_frame>5 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Glucose Levels Before Lunch</title>
          <description>The blood glucose levels will be assessed prior to lunch using a glucose meter.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" spread="16"/>
                    <measurement group_id="O2" value="172" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Glucose Levels at Bedtime</title>
        <description>The blood glucose levels will be assessed at bedtime using a glucose meter.</description>
        <time_frame>5 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Glucose Levels at Bedtime</title>
          <description>The blood glucose levels will be assessed at bedtime using a glucose meter.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157" spread="18"/>
                    <measurement group_id="O2" value="171" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Glucose Levels Before Dinner</title>
        <description>The blood glucose levels will be assessed before dinner using a glucose meter.</description>
        <time_frame>5 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Glucose Levels Before Dinner</title>
          <description>The blood glucose levels will be assessed before dinner using a glucose meter.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" spread="19"/>
                    <measurement group_id="O2" value="160" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hypoglycemia</title>
        <description>The number of occurrences of hypoglycemia (blood glucose levels &lt; 70 mg/dL) will be recorded.</description>
        <time_frame>5 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypoglycemia</title>
          <description>The number of occurrences of hypoglycemia (blood glucose levels &lt; 70 mg/dL) will be recorded.</description>
          <units>number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hyperglycemia</title>
        <description>The number of occurrences of hyperglycemia (blood glucose levels &gt; 260 mg/dL) will be recorded.</description>
        <time_frame>5 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hyperglycemia</title>
          <description>The number of occurrences of hyperglycemia (blood glucose levels &gt; 260 mg/dL) will be recorded.</description>
          <units>number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Blood Glucose Readings Within 100-140 mg/dL Range</title>
        <description>The number of blood glucose readings that are in the target range of 100-140 mg/dL will be recorded.</description>
        <time_frame>5 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Blood Glucose Readings Within 100-140 mg/dL Range</title>
          <description>The number of blood glucose readings that are in the target range of 100-140 mg/dL will be recorded.</description>
          <units>number of readings</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Number of Days of Hospital Stay</title>
        <description>The average number of days in the hospital for subjects will be calculated.</description>
        <time_frame>5 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Number of Days of Hospital Stay</title>
          <description>The average number of days in the hospital for subjects will be calculated.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="7.5"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>The total number of subject deaths during hospital stay will be recorded.</description>
        <time_frame>5 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>The total number of subject deaths during hospital stay will be recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects That Experienced Hospital Complications</title>
        <description>The total number of subjects in which hospital complications occurred prior to discharge will be recorded. These complications will mainly be cases of nosocomial infections, pneumonia, bacteremia, respiratory failure, and acute kidney injury [rise of serum creatinine &gt;0.5 mg/dL (or 50%) of baseline value]. Nosocomial infections will be diagnosed based on standardized Centers for Disease Control (CDC) criteria.</description>
        <time_frame>5 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects That Experienced Hospital Complications</title>
          <description>The total number of subjects in which hospital complications occurred prior to discharge will be recorded. These complications will mainly be cases of nosocomial infections, pneumonia, bacteremia, respiratory failure, and acute kidney injury [rise of serum creatinine &gt;0.5 mg/dL (or 50%) of baseline value]. Nosocomial infections will be diagnosed based on standardized Centers for Disease Control (CDC) criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily Dose of Insulin</title>
        <description>Daily dose of insulin will be recorded</description>
        <time_frame>5 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
            <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Dose of Insulin</title>
          <description>Daily dose of insulin will be recorded</description>
          <units>units/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="43"/>
                    <measurement group_id="O2" value="41" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Insulin Aspart for BG &gt; 140 mg/dL</title>
          <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;140 mg/dL.</description>
        </group>
        <group group_id="E2">
          <title>Insulin Aspart for BG &gt; 260 mg/dL</title>
          <description>Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels &gt;260 mg/dL.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Priyathama Vellanki</name_or_title>
      <organization>Emory University</organization>
      <phone>404-251-8957</phone>
      <email>priyathama.vellanki@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

